Compare NUVB & KW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NUVB | KW |
|---|---|---|
| Founded | 2018 | 1977 |
| Country | United States | United States |
| Employees | 298 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | 2007 |
| Metric | NUVB | KW |
|---|---|---|
| Price | $4.48 | $10.90 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 8 | 1 |
| Target Price | ★ $11.38 | $11.00 |
| AVG Volume (30 Days) | ★ 3.1M | 705.2K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 4.41% |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $62,633,000.00 |
| Revenue This Year | $203.82 | $81.79 |
| Revenue Next Year | $58.18 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 23.94 |
| 52 Week Low | $1.57 | $5.98 |
| 52 Week High | $9.75 | $10.99 |
| Indicator | NUVB | KW |
|---|---|---|
| Relative Strength Index (RSI) | 42.92 | 55.38 |
| Support Level | $4.06 | $10.83 |
| Resistance Level | $5.42 | $10.99 |
| Average True Range (ATR) | 0.26 | 0.02 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 26.05 | 62.50 |
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
Kennedy-Wilson Holdings Inc is a real estate investment company that owns, operates, and invests in real estate both on its own and through its investment management platform. The Company focuses on multifamily and office properties, as well as industrial and debt investments. It has two business segments; the Consolidated Portfolio includes investment activities that involve ownership of multifamily units, office, retail and industrial space, and one hotel, and The Co-Investment Portfolio segment consists of investments the Company makes with partners in which it receives fees, performance allocations that it earns on its fee-bearing capital and distributions and profits from its ownership interest in the underlying operations of its co-investments.